ClinicalTrials.gg
CompletedNCT01505647Updated Apr 12, 2017Results posted

Safety and Immunogenicity of Zoster Vaccine (ZOSTAVAX™) Made With an Alternative Manufacturing Process (AMP) (V211-042 AM1)

A Phase 3 interventional study of Zoster Vaccine, Live (AMP) and Zoster Vaccine, Live in Herpes Zoster and Shingles, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-04-12.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
498
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies testing Chickenpox Vaccine in Herpes Zoster — none open to participants now, none under way, none of them phase 3. Chickenpox Vaccine · Herpes Zoster.

Enrollment
7th of 29
498 · median 160
Started
2012
with 3 others
Phase 3
9 of 29
none open now
Registered
16th of 29
by date
Lead sponsor
15 of 29
Merck Sharp & Dohme LLC

Among the 29 studies testing Chickenpox Vaccine in Herpes Zoster, this one is the 7th largest by enrollment, is one of 4 that started in 2012, is one of 9 in phase 3, and was the 16th registered.

Herpes Zoster

299 studies on the registry are indexed under Herpes Zoster; 55 are open to participants now.

Browse Herpes Zoster studies →

Open to participants now

None of the 29 studies testing Chickenpox Vaccine in Herpes Zoster is open now. The open studies under Herpes Zoster, anywhere →

About Chickenpox Vaccine

Chickenpox Vaccine: first FDA approval 1995 (Varivax). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 37 Herpes Zoster studies recruiting now, 26 (70%) set no upper age limit and 6 (16%) stop at 75 or younger; 3 take children under 18; 13 take healthy volunteers.

This study: 50 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 29 studies testing Chickenpox Vaccine in Herpes Zoster as a file.
02

Study summary

This study will determine whether ZOSTAVAX™ made with an alternative manufacturing process [ZOSTAVAX™ (AMP)] is well tolerated and immunogenic, and has a comparable immune response to ZOSTAVAX™.

03

Conditions studied

  • Herpes Zoster
  • Shingles

Browse trials for

04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • No fever on day of vaccination
  • History of varicella or residence in a VZV-endemic area for ≥30 years
  • Females of must have a negative pregnancy test and must agree to use acceptable methods of

Exclusion criteria

Exclusion Criteria:

  • History of reaction to any vaccine component
  • Prior receipt of any varicella or zoster vaccine
  • Prior history of herpes zoster
  • Have recently had another vaccination
  • Pregnant or breastfeeding
  • Use of therapy
  • Known or suspected immune dysfunction
  • Concomitant antiviral therapy
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
498 participants (actual)

Study arms

  • Experimental
    ZOSTAVAX™ (AMP)

    ZOSTAVAX™ manufactured with an alternative process

    Biological: Zoster Vaccine, Live (AMP)

  • Active comparator
    ZOSTAVAX™

    ZOSTAVAX™ manufactured with the current process

    Biological: Zoster Vaccine, Live

Interventions

06

What researchers measure

Primary outcomes

  1. Geometric Mean Titer (GMT) of Varicella-Zoster Virus (VZV) Antibody

    VZV antibody titers were determined by glycoprotein enzyme-linked immunosorbent assay (gpELISA)

    Time frame: Day 1 and Week 6 postvaccination

  2. Geometric Mean Fold Rise (GMFR) in VZV Antibody Titers

    VZV antibody titers were determined by gpELISA. The GMFR reports the geometric mean of the ratio of individual participant VZV antibody titers at Week 6 / Day 1 (Baseline).

    Time frame: Day 1 (Baseline) to Week 6 postvaccination

Secondary outcomes

  1. Number of Participants With One or More Adverse Experiences (AEs)

    An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the product. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an adverse experience.

    Time frame: Day 1 to Day 42 postvaccination

  2. Number of Participants With One or More Serious Adverse Experience (SAE) Day 1 to 42 Postvaccination

    An SAE is defined as any adverse event that results in death, is life threatening, results in a persistent or significant disability/incapacity, results in hospitalization or prolongs an existing hospitalization, is a congenital anomaly/birth defect, is a cancer, is an overdose, or is considered an "other important medical event" based on medical judgement

    Time frame: Day 1 to Day 42 postvaccination

  3. Number of Participants With One or More Serious Adverse Experience Day 1 to 182 Postvaccination

    An SAE is defined as any adverse event that results in death, is life threatening, results in a persistent or significant disability/incapacity, results in hospitalization or prolongs an existing hospitalization, is a congenital anomaly/birth defect, is a cancer, is an overdose, or is considered an "other important medical event" based on medical judgement

    Time frame: Day 1 to Day 182 postvaccination

07

Results

Posted Jul 3, 2013

Participant flow

Day 1 Through Day 42 Follow-up
Participant flow — Day 1 Through Day 42 Follow-up
MilestoneZOSTAVAX™ (AMP)ZOSTAVAX™
Started332166
Vaccinated331166
Completed329166
Not completed30
Withdrew: Lost to follow-up10
Withdrew: Physician decision10
Withdrew: Withdrawal by subject10
Day 43 Through Day 182 Follow-up
Participant flow — Day 43 Through Day 182 Follow-up
MilestoneZOSTAVAX™ (AMP)ZOSTAVAX™
Started329166
Completed328163
Not completed13
Withdrew: Death01
Withdrew: Lost to follow-up12

Outcome measures

PrimaryGeometric Mean Titer (GMT) of Varicella-Zoster Virus (VZV) Antibody

VZV antibody titers were determined by glycoprotein enzyme-linked immunosorbent assay (gpELISA)

Time frame:
Day 1 and Week 6 postvaccination
Reported as:
Geometric mean · Units/mL
Geometric Mean Titer (GMT) of Varicella-Zoster Virus (VZV) Antibody
Units/mLZOSTAVAX™ (AMP)ZOSTAVAX™
Day 1 postvaccination; n = 330, 166235.7 (211.7 to 262.5)208.2 (176.4 to 245.7)
Week 6 postvaccination; n = 320, 164532.6 (489.2 to 579.9)457.1 (403.3 to 518.0)
Statistical analysis
  • ZOSTAVAX™ (AMP) vs ZOSTAVAX™ · Longitudinal regression model · p = <0.001 (The threshold for statistical significance is 0.025 (1-sided). The P-value was not adjusted.) · Gmt ratio: 1.08 · 95% CI 0.98 to 1.20The analyzed GMT ratio, 95% confidence interval, and P-value were based on a longitudinal regression model adjusting for age and vaccination group
PrimaryGeometric Mean Fold Rise (GMFR) in VZV Antibody Titers

VZV antibody titers were determined by gpELISA. The GMFR reports the geometric mean of the ratio of individual participant VZV antibody titers at Week 6 / Day 1 (Baseline).

Time frame:
Day 1 (Baseline) to Week 6 postvaccination
Reported as:
Geometric mean · Ratio
Geometric Mean Fold Rise (GMFR) in VZV Antibody Titers
RatioZOSTAVAX™ (AMP)ZOSTAVAX™
Geometric Mean Fold Rise (GMFR) in VZV Antibody Titers2.3 (2.1 to 2.4)2.2 (2.0 to 2.5)
Statistical analysis
  • ZOSTAVAX™ (AMP) · t-test, 1 sided · p = <0.001 (The threshold for statistical significance is 0.025 (1-sided). The P-value was not adjusted.)
SecondaryNumber of Participants With One or More Adverse Experiences (AEs)

An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the product. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an adverse experience.

Time frame:
Day 1 to Day 42 postvaccination
Reported as:
Number · Participants
Number of Participants With One or More Adverse Experiences (AEs)
ParticipantsZOSTAVAX™ (AMP)ZOSTAVAX™
Number of Participants With One or More Adverse Experiences (AEs)20599
SecondaryNumber of Participants With One or More Serious Adverse Experience (SAE) Day 1 to 42 Postvaccination

An SAE is defined as any adverse event that results in death, is life threatening, results in a persistent or significant disability/incapacity, results in hospitalization or prolongs an existing hospitalization, is a congenital anomaly/birth defect, is a cancer, is an overdose, or is considered an "other important medical event" based on medical judgement

Time frame:
Day 1 to Day 42 postvaccination
Reported as:
Number · Participants
Number of Participants With One or More Serious Adverse Experience (SAE) Day 1 to 42 Postvaccination
ParticipantsZOSTAVAX™ (AMP)ZOSTAVAX™
Number of Participants With One or More Serious Adverse Experience (SAE) Day 1 to 42 Postvaccination12
SecondaryNumber of Participants With One or More Serious Adverse Experience Day 1 to 182 Postvaccination

An SAE is defined as any adverse event that results in death, is life threatening, results in a persistent or significant disability/incapacity, results in hospitalization or prolongs an existing hospitalization, is a congenital anomaly/birth defect, is a cancer, is an overdose, or is considered an "other important medical event" based on medical judgement

Time frame:
Day 1 to Day 182 postvaccination
Reported as:
Number · Participants
Number of Participants With One or More Serious Adverse Experience Day 1 to 182 Postvaccination
ParticipantsZOSTAVAX™ (AMP)ZOSTAVAX™
Number of Participants With One or More Serious Adverse Experience Day 1 to 182 Postvaccination48

Adverse events

Collected over Serious Adverse Events: Day 1 to Day 182 postvaccination; Other Adverse Events: Day 1 to Day 42 postvaccination. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ZOSTAVAX™ (AMP)—4/330 (1.2%)186/330 (56.4%)
ZOSTAVAX™—8/166 (4.8%)85/166 (51.2%)
Most frequent serious events
Showing 10 of 18
Most frequent serious events
EventZOSTAVAX™ (AMP)ZOSTAVAX™
Bile duct stoneHepatobiliary disorders0/3301/166
Traumatic liver injuryInjury, poisoning and procedural complications0/3301/166
Cardiac failure congestiveCardiac disorders0/3301/166
VertigoEar and labyrinth disorders0/3301/166
Gastrointestinal haemorrhageGastrointestinal disorders0/3301/166
Ileus paralyticGastrointestinal disorders0/3301/166
CholangitisHepatobiliary disorders0/3301/166
Gallbladder perforationHepatobiliary disorders0/3301/166
Enterocolitis infectiousInfections and infestations0/3301/166
ConcussionInjury, poisoning and procedural complications0/3301/166
Most frequent other events
Most frequent other events
EventZOSTAVAX™ (AMP)ZOSTAVAX™
Injection-site painGeneral disorders146/33068/166
Injection-site erythemaGeneral disorders135/33066/166
Injection-site swellingGeneral disorders106/33053/166
Injection-site pruritusGeneral disorders22/33013/166

Baseline characteristics

Age, Continuous
Age, Continuous(years)ZOSTAVAX™ (AMP)ZOSTAVAX™Total
Mean62.9 ± 7.162.4 ± 7.062.8 ± 7.1
Sex: Female, Male
Sex: Female, Male(Participants)ZOSTAVAX™ (AMP)ZOSTAVAX™Total
Female19699295
Male13667203
08

Study locations

No study locations are listed for this record.

09

References and documents

Individual participant data

Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2012, a primary completion of Jul 2012 and a completion of Nov 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2013, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 4, 2012
First posted
Jan 6, 2012
Start
Apr 2012
Primary completionActual
Jul 2012
CompletionActual
Nov 2012
Results first posted
Jul 3, 2013
Last update
Apr 12, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 12, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01505647
Responsible party
Sponsor
First posted
Jan 6, 2012
Start date
Apr 2012
Primary completion
Jul 2012
Completion
Nov 2012
Results posted
Jul 3, 2013
Last update
Apr 12, 2017

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Chickenpox Vaccine

Start the discussion